# The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes

Study · id `cardio:ct-nct02695810` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02695810](<https://clinicaltrials.gov/study/NCT02695810>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT02695810

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

## Technical summary

Registry record NCT02695810. Randomized; no masking; primary purpose prevention. Start 2016-02-24 (actual); primary completion 2018-09-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT02695810, source copy `cardio:ctgov-nct02695810-2019-10-07`, retrieved 2026-11-18)
- Started: 2016-02-24 (actual) (ClinicalTrials.gov record NCT02695810, source copy `cardio:ctgov-nct02695810-2019-10-07`, retrieved 2026-11-18)
- Primary completion: 2018-09-20 (actual) (ClinicalTrials.gov record NCT02695810, source copy `cardio:ctgov-nct02695810-2019-10-07`, retrieved 2026-11-18)
- Completion: 2019-01-13 (actual) (ClinicalTrials.gov record NCT02695810, source copy `cardio:ctgov-nct02695810-2019-10-07`, retrieved 2026-11-18)
- Countries: Denmark (ClinicalTrials.gov record NCT02695810, source copy `cardio:ctgov-nct02695810-2019-10-07`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02695810-2019-10-07`, retrieved 2026-11-18)

## The registry's words

- Brief title: The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes
- Condition: Prediabetic State
- Condition: Obesity
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Metformin
- Intervention (Behavioral): Exercise
- Lead sponsor: Steno Diabetes Center Copenhagen
- Lead sponsor class: OTHER
- Collaborator: The Novo Nordic Foundation
- Collaborator class: OTHER
- Collaborator: Copenhagen University Hospital, Rigshospitalet
- Collaborator class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: Steno Diabetes Center Copenhagen (`cardio:org-steno-diabetes-center-copenhagen`)
- Registry lists this organization as a collaborator: Copenhagen University Hospital, Rigshospitalet (`cardio:org-copenhagen-university-hospital-rigshospitalet`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial (`cardio:pubmed-33064182`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c677c743ba3bc3211825c332c5719d57399d0ec75bb0580a8bb10be581451183
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
